You cannot register for this webinar

This webinar will explore a new clinical trial investigating a combination of three targeted therapies—Pemigatinib, Bevacizumab, and Atezolizumab—for patients with advanced cholangiocarcinoma (bile duct cancer) that has a specific genetic alteration known as FGFR2 fusion or rearrangement. This genetic change is present in approximately 15% of patients with this cancer and can contribute to tumor resistance against the immune system and existing treatments. While Pemigatinib alone has shown some benefit, this trial seeks to improve patient outcomes by adding Bevacizumab, which targets blood vessel growth, and Atezolizumab, which enhances the immune response. By combining these therapies, researchers aim to overcome resistance mechanisms and create a more effective treatment strategy. The study will evaluate the safety and effectiveness of this combination while also analyzing how it alters the tumor environment to better support the immune system in fighting cancer. This research represents a promising step toward developing more effective treatment options for patients with this challenging disease.